サンプル依頼リスト カート
  • English
  • Korean
表紙：心不全（HF）：7市場の医薬品予測と市場分析 - 更新版
市場調査レポート
商品コード
1599199

心不全（HF）：7市場の医薬品予測と市場分析 - 更新版

Heart Failure: Seven-Market Drug Forecast and Market Analysis - Update

出版日
発行
GlobalData
ページ情報
英文 137 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
心不全（HF）：7市場の医薬品予測と市場分析 - 更新版
出版日: 2024年11月11日
発行: GlobalData
ページ情報: 英文 137 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）における心不全（HF）治療薬の売上は、2022年に約135億米ドルと推定されます。心不全（HF）の市場規模は、2032年までにCAGRで9.6%の高成長を示し、予測期間末に337億米ドルの売上に達すると予測されます。

予測期間におけるHF市場成長の主な促進要因

  • Bayerのケレンディア（ファインレノン）の適応拡大が見込まれること
  • 複数の経口剤と注射剤の発売
  • 世界の慢性心不全の有病率の増加

予測期間にHF市場の成長を抑制する主な障壁

  • 近年のHF治療薬の高い価格
  • 心臓専門医やその他の医師が新しいHF治療薬の採用や処方に消極的であること
  • HF治療薬のジェネリック医薬品の普及により、高価格なブランド治療薬の市場浸透が困難になっていること

当レポートでは、心不全（HF）の主要7市場について調査し、心不全の概要、心不全治療薬市場の収益と予測、パイプラインの分析、現在と将来の競合の分析などを提供しています。

目次

第1章 心不全（HF）：エグゼクティブサマリー - 2024年10月更新、2024年10月24日までの出来事に基づく

  • HF市場は2022年～2032年に力強い成長を示す
  • CV医薬品の適応拡大が市場成長を促進
  • HF市場では、確立された治療法があるにもかかわらず、アンメットニーズが残っている
  • HF市場は注射剤が主流になる
  • 医師の考え

第2章 イントロダクション - 2024年10月更新、2024年10月24日までの出来事に基づく

  • カタリスト
  • 関連レポート

第3章 疾患の概要

  • 病因と病態生理学
    • 病因
    • 病態生理学
    • 関心を集めているバイオマーカー/ターゲット
  • 分類または段階分けのシステム
  • 予後

第4章 疫学

  • 疾患の背景
  • 危険因子と合併症
  • 世界の過去の動向
  • 予測手法
  • HFの疫学的予測（2022年～2032年）
    • HFの発症者数
    • HFの発症者数：年齢別
    • HFの発症者数：性別
    • HFの発症者数：駆出率別
    • 急性HFでの入院
    • 症状に基づく急性HFの入院
    • 急性HFの入院期間
    • 急性HF後の退院後30日以内の再入院
    • HFの有病者数
    • HFの有病者数：年齢別
    • HFの有病者数：性別
    • HFの有病者数：駆出率別
    • HFの有病者数：New York Heart Associationクラス別
    • 左室駆出率が保たれたHF（左室駆出率50%以下）の有病者数：New York Heart Associationクラス別
    • 左室駆出率が軽度低下したHF（左室駆出率40～49%）の有病者数：New York Heart Associationクラス別
    • 左室駆出率が低下したHF（左室駆出率40%未満）の有病者数：New York Heart Associationクラス別
    • HFの有病者数：American College of Cardiology Foundation/American Heart Associationステージ別
  • 議論
    • 疫学的予測の考察
    • COVID-19の影響
    • 分析の限界
    • 分析の強み

第5章 疾病管理 - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 診断と治療の概要
  • 疾病管理に関するKOLの見識

第6章 現在の治療オプション - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 概要

第7章 アンメットニーズと機会の評価 - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 概要
  • 駆出率が保たれたHF患者に対する治療法の不足
  • 急性HFの治療法の不足
  • HF治療のコンプライアンスと最適な管理
  • HF発症リスクのある患者に対する予防療法

第8章 R&D戦略 - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 概要
    • その他の適応症で承認された治療法の適応拡大
    • 製品パイプラインを拡大するための合併と買収
  • 臨床試験デザイン
    • HFの臨床エンドポイント
    • 包含基準と除外基準

第9章 パイプラインの評価 - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 概要
  • 臨床開発中の有望な医薬品

第10章 パイプラインの評価の分析 - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 概要
  • 競合の評価

第11章 現在の企業と将来の企業 - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 概要
  • 取引の動向

第12章 市場の見通し - 2024年10月更新、2024年10月24日までの出来事に基づく

  • 世界市場
    • 予測
    • 促進要因と障壁 - 世界の問題
  • 米国
    • 予測
    • 主な出来事
    • 促進要因と障壁
  • 欧州5ヶ国
    • 予測
    • 主な出来事
    • 促進要因と障壁
  • 日本
    • 予測
    • 主な出来事
    • 促進要因と障壁

第13章 付録

図表

List of Tables

  • Table 1: Heart failure: key metrics in the 7MM
  • Table 2: Types of chronic HF
  • Table 3: Causes of HF
  • Table 4: Compensatory mechanisms in HF patients
  • Table 5: Symptoms of HF
  • Table 6: Types of chronic HF
  • Table 7: Comparison of two HF classification systems
  • Table 8: Risk factors and comorbidities for HF
  • Table 9: Treatment guidelines for HF
  • Table 10: Top 10 deals by value, 2019-24
  • Table 11: HF market - global drivers and barriers, 2022-32
  • Table 12: Key events impacting sales for HF in the US, 2022-32
  • Table 13: HF market - drivers and barriers in the US, 2022-32
  • Table 14: Key events impacting sales for HF in the 5EU, 2022-32
  • Table 15: HF market - drivers and barriers in the 5EU, 2022-32
  • Table 16: Key events impacting sales for HF in Japan, 2022-32
  • Table 17: HF market - drivers and barriers in Japan, 2022-32
  • Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

  • Figure 1: Global sales forecast by country for HF in 2022 and 2032
  • Figure 2: Analysis of the company portfolio gap in HF during the forecast period
  • Figure 3: Competitive assessment of the injectable late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period
  • Figure 4: Competitive assessment of the oral late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period
  • Figure 5: Changes in cardiac structure in HF
  • Figure 6: 7MM, diagnosed incidence of HF (cases per 100,000 population), men and women, all ages, 2022
  • Figure 7: 7MM, diagnosed prevalence of HF (%), men and women, all ages, 2022
  • Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of HF
  • Figure 9: 7MM, sources used to forecast the diagnosed incident cases of HF by EF
  • Figure 10: 7MM, sources used to forecast the hospitalization for acute HF
  • Figure 11: 7MM, sources used to forecast the hospitalizations for acute HF by presentation
  • Figure 12: 7MM, sources used to forecast the hospital LoS for acute HF
  • Figure 13: 7MM, sources used to forecast the re-admissions within 30 days post-discharge after acute HF hospitalization
  • Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of HF
  • Figure 15: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
  • Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of HF by NYHA class
  • Figure 17: 7MM, sources used to forecast the diagnosed prevalent cases of HF-PEF, HF-mrEF, and HF-REF by NYHA class
  • Figure 18: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
  • Figure 19: 7MM, diagnosed incident cases of HF, N, both sexes, all ages, 2022
  • Figure 20: 7MM, diagnosed incident cases of HF by age, N, both sexes, 2022
  • Figure 21: 7MM, diagnosed incident cases of HF by sex, N, all ages, 2022
  • Figure 22: 7MM, diagnosed incident cases of HF by EF, N, both sexes, all ages, 2022
  • Figure 23: 7MM, hospitalizations for acute HF, N, both sexes, all ages, 2022
  • Figure 24: 7MM, acute HF hospitalizations based on presentation, N, both sexes, all ages, 2022
  • Figure 25: 7MM, hospital LoS for acute HF, days, both sexes, all ages, 2022
  • Figure 26: 7MM, re-admissions within 30 days post-discharge after acute HF hospitalization, N, both sexes, all ages, 2022
  • Figure 27: 7MM, diagnosed prevalent cases of HF, N, both sexes, all ages, 2022
  • Figure 28: 7MM, diagnosed prevalent cases of HF by age, N, both sexes, 2022
  • Figure 29: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
  • Figure 30: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
  • Figure 31: 7MM, diagnosed prevalent cases of HF by NYHA classes, N, both sexes, all ages, 2022
  • Figure 32: 7MM, diagnosed prevalent cases of HF-PEF (LVEF >=50%) by NYHA class, N, both sexes, all ages, 2022
  • Figure 33: 7MM, diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class, N, both sexes, all ages, 2022
  • Figure 34: 7MM, diagnosed prevalent cases of HF-REF (LVEF <40%) by NYHA class, N, both sexes, all ages, 2022
  • Figure 35: 7MM, diagnosed prevalent cases of HF by ACCF/AHA stages, N, both sexes, all ages, 2022
  • Figure 36: Diagnosis algorithm for chronic HF
  • Figure 37: Unmet needs and opportunities in chronic and acute HF
  • Figure 38: Overview of the development pipeline in HF
  • Figure 39: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for HF in the 7MM during the forecast period
  • Figure 40: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of HF during the forecast period
  • Figure 41: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care (SOC)
  • Figure 42: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care (SOC)
  • Figure 43: Analysis of the company portfolio gap in HF during the forecast period
  • Figure 44: Global (7MM) sales forecast by country for HF in 2022 and 2032
  • Figure 45: Sales forecast by class for HF in the US in 2022 and 2032
  • Figure 46: Sales forecast by class for HF in the 5EU in 2022 and 2032
  • Figure 47: Sales forecast by class for HF in Japan in 2022 and 2032
目次

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the heart failure market through 2032.

GlobalData estimates sales of HF therapeutics to be approximately $13.5 billion across the 7MM in 2022. By 2032, GlobalData expects the HF market to grow at a strong compound annual growth rate (CAGR) of 9.6%, reaching sales of $33.7 billion by the end of the forecast period.

Major drivers of HF market growth over the forecast period are the -

  • Anticipated expanded indication for Bayer's Kerendia (finerenone)
  • Launch of several oral and injectable agents
  • Increase in the global prevalence of chronic HF

Major barriers that will restrict the growth of the HF market during the forecast period are the -

  • High price of recently developed HF therapies
  • General reluctance of cardiologists and other physicians to adopt and prescribe new HF therapies
  • Widespread use of generic HF drugs, making it difficult for high-priced branded therapies to penetrate the market

Scope

  • Overview of heart failure, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized heart failure therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the heart failure therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for heart failure treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the global heart failure therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM heart failure therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM heart failure therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

  • About GlobalData

1 Heart Failure: Executive Summary - Updated October 2024, Based on Events up to October 24, 2024

  • 1.1 The HF market will exhibit strong growth between 2022 and 2032
  • 1.2 Label expansions of CV drugs will fuel market growth
  • 1.3 Unmet needs remain in the HF market despite the availability of well-established therapies
  • 1.4 Injectable agents will dominate the HF market
  • 1.5 What do physicians think?

2 Introduction - Updated October 2024, Based on Events up to October 24, 2024

  • 2.1 Catalyst
  • 2.2 Related reports

3 Disease Overview

  • 3.1 Etiology and pathophysiology
    • 3.1.1 Etiology
    • 3.1.2 Pathophysiology
    • 3.1.3 Biomarkers/targets of interest
  • 3.2 Classification or staging systems
  • 3.3 Prognosis

4 Epidemiology

  • 4.1 Disease background
  • 4.2 Risk factors and comorbidities
  • 4.3 Global and historical trends
  • 4.4 Forecast methodology
    • 4.4.1 Sources
    • 4.4.2 Forecast assumptions and methods
    • 4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
    • 4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by ejection fraction
    • 4.4.5 Forecast assumptions and methods: hospitalizations for acute HF
    • 4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
    • 4.4.7 Forecast assumptions and methods: hospital length of stay days for acute HF hospitalizations
    • 4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
    • 4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
    • 4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by ejection fraction
    • 4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by New York Heart Association classes
    • 4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF with preserved ejection fraction (left ventricular ejection fraction >=50%) by New York Heart Association class
    • 4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricular ejection fraction 40-49%) by New York Heart Association class
    • 4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF with reduced ejection fraction (left ventricular ejection fraction <40%) by New York Heart Association class
    • 4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
  • 4.5 Epidemiological forecast for HF (2022-32)
    • 4.5.1 Diagnosed incident cases of HF
    • 4.5.2 Age-specific diagnosed incident cases of HF
    • 4.5.3 Sex-specific diagnosed incident cases of HF
    • 4.5.4 Diagnosed incident cases of HF by ejection fraction
    • 4.5.5 Hospitalizations for acute HF
    • 4.5.6 Acute HF hospitalizations based on presentation
    • 4.5.7 Hospital length of stay for acute HF
    • 4.5.8 Re-admissions within 30 days post-discharge after acute HF
    • 4.5.9 Diagnosed prevalent cases of HF
    • 4.5.10 Age-specific diagnosed prevalent cases of HF
    • 4.5.11 Sex-specific diagnosed prevalent cases of HF
    • 4.5.12 Diagnosed prevalent cases of HF by ejection fraction
    • 4.5.13 Diagnosed prevalent cases of HF by New York Heart Association class
    • 4.5.14 Diagnosed prevalent cases of HF with preserved ejection fraction (left ventricle ejection fraction >=50%) by New York Heart Association class
    • 4.5.15 Diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricle ejection fraction 40-49%) by New York Heart Association class
    • 4.5.16 Diagnosed prevalent cases of HF with reduced ejection fraction (left ventricle ejection fraction <40%) by New York Heart Association class
    • 4.5.17 Diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
  • 4.6 Discussion
    • 4.6.1 Epidemiological forecast insight
    • 4.6.2 COVID-19 impact
    • 4.6.3 Limitations of the analysis
    • 4.6.4 Strengths of the analysis

5 Disease Management - Updated October 2024, Based on Events up to October 24, 2024

  • 5.1 Diagnosis and treatment overview
  • 5.2 KOL insights on disease management

6 Current Treatment Options - Updated October 2024, Based on Events up to October 24, 2024

  • 6.1 Overview

7 Unmet Needs and Opportunity Assessment - Updated October 2024, Based on Events up to October 24, 2024

  • 7.1 Overview
  • 7.2 Lack of therapies for HF with preserved ejection fraction patients
  • 7.3 Lack of therapies for acute HF
  • 7.4 Compliance and optimal management of HF treatments
  • 7.5 Preventative therapies for patients at risk of developing HF

8 R&D Strategies - Updated October 2024, Based on Events up to October 24, 2024

  • 8.1 Overview
    • 8.1.1 Label expansion for therapies approved for other indications
    • 8.1.2 Mergers and acquisitions to expand the product pipeline
  • 8.2 Clinical trials design
    • 8.2.1 Clinical endpoints for HF
    • 8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment - Updated October 2024, Based on Events up to October 24, 2024

  • 9.1 Overview
  • 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis - Updated October 2024, Based on Events up to October 24, 2024

  • 10.1 Overview
  • 10.2 Competitive assessment

11 Current and Future Players - Updated October 2024, Based on Events up to October 24, 2024

  • 11.1 Overview
  • 11.2 Deal-making trends

12 Market Outlook - Updated October 2024, Based on Events up to October 24, 2024

  • 12.1 Global markets
    • 12.1.1 Forecast
    • 12.1.2 Drivers and barriers - global issues
  • 12.2 US
    • 12.2.1 Forecast
    • 12.2.2 Key events
    • 12.2.3 Drivers and barriers
  • 12.3 5EU
    • 12.3.1 Forecast
    • 12.3.2 Key events
    • 12.3.3 Drivers and barriers
  • 12.4 Japan
    • 12.4.1 Forecast
    • 12.4.2 Key events
    • 12.4.3 Drivers and barriers

13 Appendix

  • 13.1 Bibliography
  • 13.2 Abbreviations
  • 13.3 Methodology
    • 13.3.1 Forecasting methodology
  • 13.4 Primary research - KOLs interviewed for this report
    • 13.4.1 KOLs
  • 13.5 Primary research - prescriber survey
  • 13.6 About the authors
    • 13.6.1 Analyst
    • 13.6.2 Therapy Area Director
    • 13.6.3 Epidemiologist
    • 13.6.4 Vice President of Disease Intelligence and Epidemiology
    • 13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence
  • Contact Us